Abstract
Community-acquired pneumonia is a major cause of morbidity and mortality in the United States, leading to 1.5 million hospitalizations and at least 200 000 deaths annually. The 2019 American Thoracic Society/Infectious Diseases Society of America clinical practice guideline on diagnosis and treatment of adults with community-acquired pneumonia provides an evidence-based overview of this common illness. Here, 2 experts, a general internist who served as the co-primary author of the guidelines and a pulmonary and critical care physician, debate the management of a patient hospitalized with community-acquired pneumonia. They discuss disease severity stratification methods, whether to use adjunctive corticosteroids, and when to prescribe empirical treatment for multidrug-resistant organisms such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Original language | English (US) |
---|---|
Pages (from-to) | 1719-1726 |
Number of pages | 8 |
Journal | Annals of internal medicine |
Volume | 174 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2021 |
Externally published | Yes |
ASJC Scopus subject areas
- Internal Medicine